Literature DB >> 17059162

Breast cancer: trends, risks, treatments, and effects.

London Draper1.   

Abstract

Breast cancer is the most common cancer and the second leading cause of cancer-related death for women in the United States (National Center for Chronic Disease Prevention and Health Promotion, 2006). Despite the plethora of readily available information, women die of this disease every day. Major strides have been made in early detection and treatment of breast cancer in recent years. However, more work remains. One in 8 (12%) U.S. women 90 years or younger will develop breast cancer sometime during her life (overall lifetime risk). Approximately 200,000 U.S. women and 1,500 U.S. men develop breast cancer each year. The three greatest risks for developing breast cancer are "female sex, increasing age, and family history of breast cancer" (Office of Genomics and Disease Prevention, 2006, p. 1).

Entities:  

Mesh:

Year:  2006        PMID: 17059162     DOI: 10.1177/216507990605401004

Source DB:  PubMed          Journal:  AAOHN J        ISSN: 0891-0162


  11 in total

1.  Expression of aryl hydrocarbon receptor in relation to p53 status and clinicopathological parameters in breast cancer.

Authors:  Zheng-Dong Li; Kai Wang; Xin-Wei Yang; Zhi-Gang Zhuang; Jian-Jun Wang; Xiao-Wen Tong
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

2.  Ethanol-induced oxidative stress is associated with EGF receptor phosphorylation in MCF-10A cells overexpressing CYP2E1.

Authors:  Angel León-Buitimea; Lourdes Rodríguez-Fragoso; Fredine T Lauer; Harmony Bowles; Todd A Thompson; Scott W Burchiel
Journal:  Toxicol Lett       Date:  2011-12-28       Impact factor: 4.372

3.  Gene expression profiling of mammary glands at an early stage of DMBA-induced carcinogenesis in the female Sprague-Dawley rat.

Authors:  Michela Padovani; Robert Cheng
Journal:  Eur J Oncol       Date:  2016-03-22

4.  Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells.

Authors:  Shyam N Sundar; Crystal N Marconett; Victor B Doan; Jamin A Willoughby; Gary L Firestone
Journal:  Carcinogenesis       Date:  2008-09-10       Impact factor: 4.944

Review 5.  EGFR may couple moderate alcohol consumption to increased breast cancer risk.

Authors:  Christopher P Mill; Julia A Chester; David J Riese
Journal:  Breast Cancer (Dove Med Press)       Date:  2009-10-05

6.  Down-regulation of estrogen receptor-alpha and rearranged during transfection tyrosine kinase is associated with withaferin a-induced apoptosis in MCF-7 breast cancer cells.

Authors:  Xuan Zhang; Ridhwi Mukerji; Abbas K Samadi; Mark S Cohen
Journal:  BMC Complement Altern Med       Date:  2011-10-06       Impact factor: 3.659

7.  Anticancer pyridines induce G2/M arrest and apoptosis via p53 and JNK upregulation in liver and breast cancer cells.

Authors:  Vasilis P Androutsopoulos; Demetrios A Spandidos
Journal:  Oncol Rep       Date:  2017-11-28       Impact factor: 3.906

8.  Rosmanol induces breast cancer cells apoptosis by regulating PI3K/AKT and STAT3/JAK2 signaling pathways.

Authors:  Dongjun Jiang; Jiaqi Xu; Sitong Liu; Moussa Ide Nasser; Wei Wei; Tianjiao Mao; Xintong Liu; Xiaopan Zou; Jiang Li; Xiaomeng Li
Journal:  Oncol Lett       Date:  2021-07-01       Impact factor: 2.967

9.  NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.

Authors:  S J Van Laere; I Van der Auwera; G G Van den Eynden; P van Dam; E A Van Marck; P B Vermeulen; L Y Dirix
Journal:  Br J Cancer       Date:  2007-08-14       Impact factor: 7.640

10.  Antiproliferative and cytostatic effects of the natural product eupatorin on MDA-MB-468 human breast cancer cells due to CYP1-mediated metabolism.

Authors:  Vasilis Androutsopoulos; Randolph R J Arroo; John F Hall; Somchaiya Surichan; Gerry A Potter
Journal:  Breast Cancer Res       Date:  2008-05-02       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.